Enhanced brain disposition and effects of Δ 9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Spiro, Adena S ^a   Wong, Alexander ^a   Boucher, Aurélie A ^a   Arnold, Jonathon C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; TETRAHYDROCANNABINOLIC ACID; ABC TRANSPORTER; ABCB1B PROTEIN, MOUSE; ABCG2 PROTEIN, MOUSE; BCRP PROTEIN, MOUSE; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RETENTION; ENZYME ACTIVITY; INDUCED HYPOTHERMIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECTUM TEMPERATURE; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; GENETICS; HYPOTHERMIA; METABOLISM; MOUSE MUTANT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; FEMALE; HYPOTHERMIA; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; PSYCHOTROPIC DRUGS; TETRAHYDROCANNABINOL;

EID: 84859973877     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035937     Document Type: Article

References (55)

1. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM, (2008) Gene-environment interplay between cannabis and psychosis. Schizophr Bull 34: 1111-1121.
2. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, et al. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57: 1117-1127.
3. O'Tuathaigh CM, Hryniewiecka M, Behan A, Tighe O, Coughlan C, et al. Chronic adolescent exposure to Delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 35: 2262-2273.
4. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, et al. (2007a) Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192: 325-336.
5. Boucher AA, Hunt GE, Karl T, Micheau J, McGregor IS, et al. (2007b) Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 149: 861-870.
6. Boucher AA, Hunt GE, Micheau J, Huang X, McGregor IS, et al. (2011b) The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol 14: 631-643.
7. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, et al. (2011) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13: 861-876.
8. Hall MD, Handley MD, Gottesman MM, (2009) Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30: 546-556.
9. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, et al. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287.
10. Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, et al. (2003) Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 49: 230-238.
11. Schinkel AH, (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8: 161-170.
12. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, et al. (2005) Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 33: 219-224.
13. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, et al. (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52: 333-346.
14. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165-174.
15. Tournier N, Decleves X, Saubamea B, Scherrmann JM, Cisternino S, (2011) Opioid transport by ATP-Binding Cassette (ABC) Transporters at the Blood-Brain Barrier: Implications for Neuropsychopharmacology. Curr Pharm Des.
16. Urquhart BL, Kim RB, (2009) Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65: 1063-1070.
17. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, et al. (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13: 6440-6449.
18. Yang JJ, Milton MN, Yu S, Liao M, Liu N, et al. (2010) P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett 4: 201-212.
19. Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, et al. (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15: 2344-2351.
20. Benyamina A, Bonhomme-Faivre L, Picard V, Sabbagh A, Richard D, et al. (2009) Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol Biol Psychiatry 33: 1270-1274.
21. Holland ML, Allen JD, Arnold JC, (2008) Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol 591: 128-131.
22. Holland ML, Lau DT, Allen JD, Arnold JC, (2007) The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 152: 815-824.
23. Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, et al. (2006) The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol 71: 1146-1154.
24. Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, et al. (2006) Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells. Br J Pharmacol 148: 682-687.
25. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, et al. (2006) Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther 317: 850-857.
26. Bonhomme-Faivre L, Benyamina A, Reynaud M, Farinotti R, Abbara C, (2008) Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict Biol 13: 295-300.
27. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99: 15649-15654.
28. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 94: 4028-4033.
29. Gunasekaran N, Long LE, Dawson BL, Hansen GH, Richardson DP, et al. (2009) Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. Br J Pharmacol 158: 1330-1337.
30. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, et al. (2008) Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33: 1113-1126.
31. Klein C, Karanges E, Spiro A, Wong A, Spencer J, et al. (2011) Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl).
32. Breedveld P, Beijnen JH, Schellens JH, (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27: 17-24.
33. Warren MS, Zerangue N, Woodford K, Roberts LM, Tate EH, et al. (2009) Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 59: 404-413.
34. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, et al. (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25: 1469-1483.
35. Wenger T, Moldrich G, (2002) The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 66: 301-307.
36. Fitton AG, Pertwee RG, (1982) Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. Br J Pharmacol 75: 409-414.
37. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ, (1995) Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23: 825-831.
38. Malone DT, Jongejan D, Taylor DA, (2009) Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 93: 91-96.
39. Morgan CJ, Curran HV, (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192: 306-307.
40. Morgan CJ, Schafer G, Freeman TP, Curran HV, (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry 197: 285-290.
41. Murphy LL, Steger RW, Smith MS, Bartke A, (1990) Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology 52: 316-321.
42. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, et al. (2006) Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 186: 226-234.
43. Hemauer SJ, Patrikeeva SL, Wang X, Abdelrahman DR, Hankins GD, et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol 80: 1080-1086.
44. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, et al. (2007) ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48 (Suppl 5): 140-149.
45. O'Brien FE, Dinan TG, Griffin BT, Cryan JF, Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings. Br J Pharmacol.
46. Potschka H, Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 51: 1333-1347.
47. Schinkel AH, Jonker JW, (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29.
48. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, et al. (2004) Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29: 551-557.
49. Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y, (2006) Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett 234: 73-80.
50. Bowers MB Jr, Mazure CM, Nelson JC, Jatlow PI, (1990) Psychotogenic drug use and neuroleptic response. Schizophr Bull 16: 81-85.
51. Hall W, Degenhardt L, Teesson M, (2004) Cannabis use and psychotic disorders: an update. Drug Alcohol Rev 23: 433-443.
52. Turner WM, Tsuang MT, (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 16: 87-95.
53. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, et al. (2004) The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7: 415-419.
54. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, Yuan HJ, et al. (2008) Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol 103: 336-341.
55. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478.